Tags

Type your tag names separated by a space and hit enter

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
J Microbiol Immunol Infect. 2020 Jun; 53(3):368-370.JM

Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Authors+Show Affiliations

Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128, China.Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA. Electronic address: xyang@salud.unm.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32205092

Citation

Wu, Dandan, and Xuexian O. Yang. "TH17 Responses in Cytokine Storm of COVID-19: an Emerging Target of JAK2 Inhibitor Fedratinib." Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi, vol. 53, no. 3, 2020, pp. 368-370.
Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368-370.
Wu, D., & Yang, X. O. (2020). TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi, 53(3), 368-370. https://doi.org/10.1016/j.jmii.2020.03.005
Wu D, Yang XO. TH17 Responses in Cytokine Storm of COVID-19: an Emerging Target of JAK2 Inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368-370. PubMed PMID: 32205092.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. AU - Wu,Dandan, AU - Yang,Xuexian O, Y1 - 2020/03/11/ PY - 2020/03/08/received PY - 2020/03/09/revised PY - 2020/03/10/accepted PY - 2020/3/25/pubmed PY - 2020/6/17/medline PY - 2020/3/25/entrez KW - COVID-19 KW - Cytokine storm KW - JAK2 inhibitor KW - SARS-CoV-2 KW - TH17 SP - 368 EP - 370 JF - Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi JO - J Microbiol Immunol Infect VL - 53 IS - 3 N2 - COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles. SN - 1995-9133 UR - https://www.unboundmedicine.com/medline/citation/32205092/TH17_responses_in_cytokine_storm_of_COVID_19:_An_emerging_target_of_JAK2_inhibitor_Fedratinib_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1684-1182(20)30065-7 DB - PRIME DP - Unbound Medicine ER -